Venture fund quintet in multimillion biotech acquisition  

2003.01.29
Five venture funds have acquired all the shares in Aarhus-based biotech company CCSS for a total of DKK 30 million
Five venture funds have acquired all the shares of the Aarhus-based biotech company CCSS for a total of DKK 30 million (USD 4.4 million) and changed its name to Visible Diagnostics, reports news agency Rapidus. Visible Diagnostics has patented a visual method for testing cervical smears for signs of cancer. The five investors are Innfond, Radiometer Venture Fond, Innovationsinvestering, Øresund Healthcare and Malmöhus Invest. Visible Diagnostics' new method makes the first screening of approximately half of all cervical smear tests considerably more effective and does not require manual analysis by highly trained and costly staff.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×